Tofacitinib
Indication
Tofacitinib for moderately to severely active ulcerative colitis (NICE TA547)
NICE TA547 - Tofacitinib for moderately to severely active ulcerative colitis
MHRA Drug Safety Update, 6 October 2021
Major Adverse Cardiovascular Events MHRA Drug Safety Update
Red
Brand:
Xeljanz
Nice TA:
547
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Gastro-intestinal system
Background
Tofacitinib is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated or the disease has responded inadequately or lost response to treatment. It is recommended only if the company provides tofacitinib with the discount agreed in the commercial arrangement.